Genocea Biosciences (GNCA) Tops Q1 EPS by 6c

Genocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.48), $0.06 better than the analyst estimate of ($0.54).

Financial Guidance

Genocea expects that its existing cash, cash equivalents and investments are sufficient to support its operating expenses, capital expenditure requirements and debt obligations into the first quarter of 2018, without assuming any receipt of proceeds from potential business development partnerships or equity financings. This guidance assumes commencing Phase 3 trials for GEN-003 for genital herpes around the end of 2017 and filing an IND for GEN-009 for cancer by the end of the year, however it is Genocea’s strategy to secure additional sources of financing in advance of starting GEN-003 Phase 3 clinical trials.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics